Market Overview

Cowen: In Biotech Earnings We Trust

Related AEGR
Mid-Afternoon Market Update: Dow Falls Over 200 Points; Catabasis Shares Spike Higher
15 Biggest Mid-Day Gainers For Thursday
Related ALXN
AbbVie Shares Double In A Year; Leerink Moves To Sidelines
The Key To Alexion's Long-Term Upside Potential, According To Credit Suisse
Tracking Dan Loeb's Third Point Portfolio - Q4 2017 Update (Seeking Alpha)
  • Cowen analysts expect most of the biotech companies to report their 3Q results in-line with or ahead of expectations.
  • The analysts believe that the Q3 results would highlight earnings growth and visibility in the biotech sector and boost investor confidence in financially driven stocks.

Cowen analysts said that the Q3 earnings season would be a “critical period” for the sector. They expect biotech companies to report impressive results for the quarter.

The analysts mentioned Q3 is typically a seasonally strong period for biotech companies, since it has more calendar selling days than Q1 as well as fewer major holidays than Q4. Currency impact is probably the only unfavorable macro trend.

“While political rhetoric over drug pricing may be keeping investors at bay, we think the Q3 earnings season could highlight the risk of not owning this sector during a period of fundamental growth and innovation,” the analysts wrote.

While politicians have vocal about drug pricing over the last several weeks, managements are likely to “use their Q3 earnings calls to highlight investments in R&D, service to patients, efforts to provide access, and benefits that new drugs provide to society,” the report added.

There are several major products that continue to post steady gains. These include:

  1. Soliris from Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)
  2. Denosumab and Kyprolis from Amgen, Inc. (NASDAQ: AMGN)
  3. Revlimid from Celgene Corporation (NASDAQ: CELG)
  4. Jakafi from Incyte Corporation (NASDAQ: INCY)
  5. Eylea from Regeneron Pharmaceuticals Inc (NASDAQ: REGN)

“We think investors may be underestimating the impact that macro factors like Obamacare and an aging U.S. population are having on broader drug utilization,” the report stated.

Cowen expects the following companies to beat the consensus expectations:
Alexion, Amgen, Celgene, Regeneron, Incyte, Emergent Biosolutions Inc (NYSE: EBS), Gilead Sciences, Inc. (NASDAQ: GILD) and PDL BioPharma Inc (NASDAQ: PDLI)

The following companies are likely to report in-line results:
Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), Biogen Inc (NASDAQ: BIIB), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Medivation Inc (NASDAQ: MDVN), United Therapeutics Corporation (NASDAQ: UTHR), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and XenoPort, Inc. (NASDAQ: XNPT)

The companies that could disappoint are:
Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) and Anacor Pharmaceuticals Inc (NASDAQ: ANAC)

Latest Ratings for AEGR

Feb 2016Bank of AmericaDowngradesNeutralUnderperform
Dec 2015GuggenheimUpgradesSellBuy
Nov 2015Bank of AmericaUpgradesUnderperformNeutral

View More Analyst Ratings for AEGR
View the Latest Analyst Ratings

Posted-In: Cowen VetrAnalyst Color Analyst Ratings


Related Articles (ALXN + AEGR)

View Comments and Join the Discussion!